Pharmaleaders TV

Breaking News

ticket title
Vyome Seals Strategic Pact With Impetis Biosciences, Unlocking a ~$57 Billion Market Horizon
NCLT Hyderabad Clears Resolution Plan: Beaufond Industries to Acquire Kobo Biotech as Going Concern
Beaufond Plc Charts European Course: Advanced Negotiations Under Way for Strategic API Supply Alliance with Netherlands Pharmaceutical Group
The Architects Of Aesthetics: How India’s Iconic Visionaries are Redefining the Global Skincare Map
MSN Labs Disrupts Diabetes Care with SEMABEST: India’s First Fully Integrated Semaglutide Follows Patent Expiry
Trump’s Tariff Gambit: Pharma & Metals in the Crossfire of Global Trade
Ethical Marketing Under Watch: NPPA & MCI Crack Down
Vyome Delivers Breakthrough 2025 Performance, Sets Stage for Next Growth Chapter
Pharma Leaders Power Brand Awards – India’s Most Prestigious Healthcare Leadership Platform
Is Plastic Surgery Safe? What Patients Should Know Before Considering It
You are here:  / Cohance Lifesciences

Cohance Lifesciences

Vyome Seals Strategic Pact With Impetis Biosciences, Unlocking a ~$57 Billion Market Horizon

Business

Vyome Seals Strategic Pact With Impetis Biosciences, Unlocking a ~$57 Billion Market Horizon

read more
NCLT Hyderabad Clears Resolution Plan: Beaufond Industries to Acquire Kobo Biotech as Going Concern

Business

NCLT Hyderabad Clears Resolution Plan: Beaufond Industries to Acquire Kobo Biotech as Going Concern

read more
Beaufond Plc Charts European Course: Advanced Negotiations Under Way for Strategic API Supply Alliance with Netherlands Pharmaceutical Group

Business

Beaufond Plc Charts European Course: Advanced Negotiations Under Way for Strategic API Supply Alliance with Netherlands Pharmaceutical Group

read more
The Architects Of Aesthetics: How India’s Iconic Visionaries are Redefining the Global Skincare Map

Business

The Architects Of Aesthetics: How India’s Iconic Visionaries are Redefining the Global Skincare Map

read more
MSN Labs Disrupts Diabetes Care with SEMABEST: India’s First Fully Integrated Semaglutide Follows Patent Expiry

Business

MSN Labs Disrupts Diabetes Care with SEMABEST: India’s First Fully Integrated Semaglutide Follows Patent Expiry

read more
Follow us
Contact us

Network 7 Meadia Group

Plot 5, NS Road No. 12, JVPD, Juhu Scheme, Mumbai, Maharashtra 400049. editorial@pharmaleaders.tv